Thymosin Beta-4

Research-Grade

Thymosin Beta-4 (Tβ4) is a 43-amino acid polypeptide that is the most abundant member of the beta-thymosin family. Originally isolated from thymic tissue (hence the name), it is actually ubiquitously expressed in virtually all nucleated cells. Its primary intracellular function is sequestering G-actin monomers, regulating actin polymerization and thus cell motility, migration, and cytoskeletal remodeling. The connection to tissue repair is direct: wound healing requires cell migration (endothelial cells, keratinocytes, fibroblasts must move into the wound bed), angiogenesis (new blood vessel formation), and extracellular matrix remodeling — all processes that depend on actin dynamics. Thymosin Beta-4 promotes all three. The most commercially recognized derivative is TB-500, a synthetic peptide corresponding to the active region (amino acids 17-23, the actin-binding domain) of Thymosin Beta-4. TB-500 is widely used in veterinary medicine (particularly equine) and the research peptide market. Full-length Thymosin Beta-4 contains additional functional domains beyond the actin-binding site, including anti-inflammatory sequences and nuclear localization signals that may contribute to gene expression regulation. Clinical development of Thymosin Beta-4 has focused on ophthalmology: RegeneRx Biopharmaceuticals developed RGN-259 (Tβ4 eye drops) for dry eye disease and neurotrophic keratopathy. Phase 2 trials showed significant improvement in corneal healing. Cardiac applications have also been explored — Tβ4 activates epicardial progenitor cells and promotes cardiac repair in mouse models of myocardial infarction. Despite extensive preclinical promise, full-length Thymosin Beta-4 has not achieved regulatory approval for systemic use. Its large size (43 amino acids) presents manufacturing and delivery challenges compared to smaller peptide fragments.